3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years

Abbott Laboratories (ABT), Stryker (SYK), and Becton Dickinson (BDX) are medical device companies with long dividend growth streaks. ABT yields 2.18%, SYK 1.13%, and BDX 2.11%. ABT plans to raise dividends, SYK has the lowest payout ratio, and BDX has the longest streak. All trade at forward P/E ratios of 15-19.

Original reporting
Published Nov 7, 2026, 1:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 1:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years — source image
Decision brief

The 30-second read

$ABTBullishLow
01

Why it matters

New dividend‑streak announcements provide fresh data for income‑oriented traders and may trigger modest buying pressure in the three stocks.

02

Market read

Income‑focused investors may add these stocks, modestly supporting the med‑tech sector and dividend‑oriented ETFs.

03

What to watch

Potential headwinds from the Exact Sciences acquisition and macro‑economic slowdown could pressure earnings.

Relevance 6/10Novelty 5/10Timing: today

Background

The article profiles three large U.S. medical‑device companies that have consistently raised dividends, emphasizing their payout ratios, cash flow, and recent quarterly performance.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott announced its 54th consecutive year of dividend increases and plans to raise the dividend next year.

Expected impact

likely modest upside as income investors buy on the dividend raise news

Evidence & confidence

Dividend streak and forward guidance are new and material for income‑focused traders.

$SYKBullishHigh confidence
Context

Stryker reported a 1.13% yield and highlighted a low payout ratio with a 7.7% organic sales increase.

Expected impact

potential modest upside as investors value the dividend safety and cash returns

Evidence & confidence

New quarterly data and dividend safety metrics give a fresh catalyst for the stock.

$BDXBullishHigh confidence
Context

Becton Dickinson announced its 55th consecutive year of dividend increases and a $2.93 bn free‑cash‑flow generation.

Expected impact

likely modest upside as the market prices the continued dividend growth

Evidence & confidence

The 55‑year streak is a fresh corporate milestone that can move the stock.

Market effects

Highlights the resilience of the medical‑device sector and may boost sector‑wide dividend‑seeking sentiment.

U.S. dividend‑focused investors may rotate into med‑tech names, modestly supporting broader indices.

Limited to markets with exposure to U.S. listed med‑device stocks.

Counterpoint

High dividend yields may mask slower growth; investors could prefer higher‑growth tech stocks.

Key entities

  • Abbott Laboratories

    U.S. medical‑device and diagnostics firm with a 54‑year dividend streak.

  • Stryker

    U.S. orthopedics and surgical equipment maker with a low payout ratio.

  • Becton Dickinson

    U.S. supplier of syringes and medical consumables with a 55‑year dividend streak.

Related articles

$AAPLMed

New Australian Data Shed Even More Light on Tax Avoidance by Big Tech (and Others), Highlight Need for Better Disclosure in the U.S.

The Australian Taxation Office released country-by-country tax reports, revealing that Apple (25% of profits in Singapore) and Visa (62% of profits in Singapore) booked significant profits in low-tax jurisdictions. Becton Dickinson reported $266.2M pretax income in the Cayman Islands with no local employees. The data highlights discrepancies between U.S. and Australian disclosures, raising concerns about tax transparency.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.